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Abstract
The HACEK organisms (Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and
Kingella species) are rare causes of infective endocarditis (IE). The objective of this study is to describe the clinical
characteristics and outcomes of patients with HACEK endocarditis (HE) in a large multi-national cohort. Patients hospitalized
with definite or possible infective endocarditis by the International Collaboration on Endocarditis Prospective Cohort Study
in 64 hospitals from 28 countries were included and characteristics of HE patients compared with IE due to other pathogens.
Of 5591 patients enrolled, 77 (1.4%) had HE. HE was associated with a younger age (47 vs. 61 years; p,0.001), a higher
prevalence of immunologic/vascular manifestations (32% vs. 20%; p,0.008) and stroke (25% vs. 17% p= 0.05) but a lower
prevalence of congestive heart failure (15% vs. 30%; p = 0.004), death in-hospital (4% vs. 18%; p = 0.001) or after 1 year
follow-up (6% vs. 20%; p = 0.01) than IE due to other pathogens (n = 5514). On multivariable analysis, stroke was associated
with mitral valve vegetations (OR 3.60; CI 1.34–9.65; p,0.01) and younger age (OR 0.62; CI 0.49–0.90; p,0.01). The overall
outcome of HE was excellent with the in-hospital mortality (4%) significantly better than for non-HE (18%; p,0.001).
Prosthetic valve endocarditis was more common in HE (35%) than non-HE (24%). The outcome of prosthetic valve and
native valve HE was excellent whether treated medically or with surgery. Current treatment is very successful for the
management of both native valve prosthetic valve HE but further studies are needed to determine why HE has a
predilection for younger people and to cause stroke. The small number of patients and observational design limit inferences
on treatment strategies. Self selection of study sites limits epidemiological inferences.
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Introduction
The HACEK group of bacteria (Haemophilus species, Aggregati-
bacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella
species) are a small, heterogeneous group of fastidious, gram-
negative bacteria that frequently colonize the oropharynx and
have long been recognised as a cause of infective endocarditis (IE).
These organisms have been historically reported as causing
infection in ,5% of patients of IE [1,2], and 0.8–6% of patients
in recent population-based studies [3–5].
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Due to the relative rarity of HACEK endocarditis (HE), the
clinical description and outcome has, of necessity, been derived
from compilation of data from small case series and case reports
[6–10]. These reports are limited by non-standardized data
collection and selective reporting of patients. Consequently, the
features of HE identified cannot be compared rigorously with
other forms of IE.
The International Collaboration on Endocarditis Prospective
Cohort Study (ICE-PCS) was designed to provide a large multi-
national resource of prospectively collected, well defined patients
of IE using a standardised data set. The objective is to improve
understanding of the clinical characteristics and outcome of IE in a
multi-national cohort of patients. In this report we describe the
characteristics of patients with HE, and compare the risk factors,
clinical characteristics, and outcomes of HE with IE caused by
other pathogens (non-HE).
Patients and Methods
Database
ICE-PCS has been described previously [11,12]. Briefly,
participating members from 64 sites in 28 countries reported
patients prospectively on a standard case report form from June
2000 through to September 2006. The case report form included
275 variables and was developed by ICE collaborators according
to standard definitions [11]. All patients were included from sites
that met performance criteria for participation. These criteria
include the following: minimum enrolment of 12 patients per year
in a centre with access to cardiac surgery; the presence of patient
identification measures to ensure consecutive enrolment and to
minimise ascertainment bias [11]; high quality data with query
resolution.
Ethical Statement
Initial institutional review board approval for ICE-PCS came
from the Duke International Centre. All participating sites had
institutional review board or ethical committee approval or a
waiver and informed consent (verbal or written) or a waiver of
consent from all patients based on local standards as required by
the Duke Coordinating Centre.
Study Sample
Patients in the ICE-PCS database were included in this study if
they had definite or possible IE according to the modified Duke’s
criteria. HACEK isolates were identified and antibiotic suscepti-
bility testing performed in the participating centres. Antibiotic
therapy was decided by the treating physician at the individual
study site.
Definitions
Infective endocarditis was defined according to the modified
Duke Criteria [13]. Infective endocarditis was considered to be left
sided if no right sided (tricuspid or pulmonary valve) vegetations
were present on echocardiographic examination, surgery, or
autopsy. Community-acquired IE was defined as signs or
symptoms of IE developing before hospitalization in a patient
without extensive out-of-hospital contact with health care inter-
ventions or systems. Hospital acquired IE was defined as symptom
onset and diagnosis occurring in a patient hospitalized for more
than 48 hours.Health care–associated infection was defined as
cases in which signs or symptoms consistent with infective
endocarditis developed before hospitalization in patients with
extensive out-of-hospital contact with health care interventions.
Extensive out of hospital intervention included one or more of the
following,(1) receipt of intravenous therapy, wound care, or
specialized nursing care at home within the 30 days prior to the
onset of IE; (2) visiting a hospital or hemodialysis clinic or
receiving intravenous chemotherapy within the 30 days before the
onset of IE; (3) hospitalization in an acute care hospital for 2 or
more days in the 90 days before the onset of IE; or (4) residing in a
nursing home or long-term care facility[14,15].
Cancer was defined as any malignant neoplasm except basal or
squamous cell carcinomas of the skin. The category ‘‘other chronic
diseases’’ included connective tissue or rheumatologic disease,
chronic liver or kidney disease, chronic neurological conditions,
and other chronic infectious and inflammatory conditions. A
diagnosis of heart failure was accepted on the basis of clinical
evaluation performed by the care team and defined according to
the New York Heart Association classification system [16]. Stroke
was defined as an acute neurological deficit of vascular aetiology
lasting more than 24 hours [17]. Systemic embolisation included
embolisation to any organ including the skin. Valve surgery
included all surgery performed on heart valves at any time during
hospitalisation regardless of urgency. Rates of surgery and
mortality include events that occurred during the index hospital-
isation and one year follow-up. Repeat IE was defined as a further
episode of IE fulfilling the modified Duke criteria. Confirmed
relapse was defined as a repeat episode caused by the same
microorganism on molecular analysis, as the preceding episode;
confirmed new infection as a repeat episode caused by a different
species or the same species but a different strain by molecular
analysis; and possible relapse as repeat episode caused by a
microorganism of the same species within 6 months of the initial
episode without molecular analysis [18].
Geographic regions
Geographic regions participating in ICE included the following:
United States (10 sites), South America (9 sites from Argentina,
Brazil, and Chile), Europe (27 sites from Austria, Croatia, France,
Germany, Greece, Ireland, Italy, the Netherlands, Romania,
Russia, Slovenia, Spain, Sweden, and the United Kingdom),
Australia and New Zealand (9 sites), Asia and Middle East (8 sites
in India, Israel, Lebanon, Malaysia, Saudi Arabia, Singapore, and
Thailand,) and South Africa (1 site).
Microbiological methods
Blood cultures and sensitivity testing was performed by
accredited laboratories using standard methods. Sensitivity testing
was most commonly those of the Clinical and Laboratory
Standards Institute (CLSI)
Statistical analysis
Continuous variables were represented as medians with 25th
and 75th percentiles. Categorical variables were represented as
frequencies and percentages of the specified group. Simple
comparisons were made with the Wilcoxon rank-sum test or the
chi square test as appropriate. For all tests, a p value of 0.05 or less
was considered statistically significant. Missing data for each
variable were excluded from the denominator. Variables found to
have a simple association with the outcome of interest (p,0.10)
were considered for the final multiple variable model in a stepwise
fashion. The variables included in the final multiple variable
adjusted regression model were selected based on a combination of
statistical significance (p,0.05) and clinical judgment. The
generalized estimating equation method was used to produce
consistent parameter estimates that measure association between
the incidence of outcome and clinical covariates while accounting
for the correlation in treatment and outcomes of patients from the
HACEK Endocarditis
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same hospital. Final parameter estimates were converted to ORs
with corresponding 95% Wald CIs. All statistical analyses were
performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Seventy seven (1.4%) of 5591 patients diagnosed with IE in
ICE-PCS had HACEK endocarditis (66 definite and 11 possible)
and PVE was present in 27 (35%). The prevalence of HE differed
significantly between the study sites (p = 0.009), with a low
prevalence in North America and a high prevalence in
Australia/New Zealand. The HE cases by region were: North
America (5/992, 0.5%), South America (8/518, 1.5%), Australia/
New Zealand (23/979, 2.3%), Europe (35/2806, 1.2%), Asia/
Middle East (5/277, 1.8%), and Africa (1/19).
Features of HE by species
The HACEK isolates were speciated in 76 (99%) cases with
Haemophilus species the most common (40%) (Table 1). Of all
HACEK species, only Kingella spp. was not associated with an
episode of prosthetic valve endocarditis (PVE). PVE was more
common in A. actinomycetemcomitans than H. parainfluenzae IE (10,
67% v 5, 18%; respectively p,0.01). Clinical manifestations of IE
of more than 1 months duration were recorded more often in A.
actinomycetemcomitans (8, 53%) and Cardiobacterium IE (6, 55%) than
H. parainfluenzae (3, 11%; both p,0.01). Aortic valve vegetations
were identified on echocardiography more commonly in Cardio-
bacterium IE (8, 89%) than in H. parainfluenzae (6, 32%; p,0.05) and
A. actinomycetemcomitans (2, 29%; p,0.05) IE. Mitral valve
endocarditis was common in H. parainfluenzae (10, 53%) and A.
actinomycetemcomitans (6, 86%). Of the five cases with Oslers’ nodes
four occurred with A. actinomycetemcomitans IE.
Clinical features of HACEK and non-HACEK endocarditis
Baseline characteristics and predisposing factors of HE are
shown in Table 2. The median age of patients with HE (47.4
years; IQR 35.6–57.1) was significantly lower than non-HE (60.5
years; IQR 45.3–72.7) and males predominated (56, 73%). Factors
more commonly associated with HE than Non-HE endocarditis
were Osler’s nodes (7% vs 3%, p = 0.02) and vascular immuno-
logical phenomena (32% vs 20%, p = 0.008) and the presence of
mechanical valves (30% vs 18%, p = 0.02). Factors less commonly
associated with HE than non-HE endocarditis were health care
provision (1% vs 24%, p,0.001), and diabetes mellitus (8% vs
18%, p = 0.02). There was no difference in the proportion with
fever or splenomegaly between HE and non-HE, nor with native
valve predisposition for IE or congenital heart disease (Table 2).
Transfers from another facility
There was no difference in the number of cases transferred from
another facility between HE (30, 39%) and non-HE (2288, 41%;
p = 0.6). In HE there were more cases transferred with native valve
endocarditis (24, 80% vs 23, 49%; p = 0.01 ), new or worsening
murmurs (20, 67% vs 19, 40% p = 0.008), regurgitation on
echocardiography (23, 77% vs 23, 49%; p = 0.02), and need for
valvular surgery (aortic valve 11, mitral valve 12) ( 23, 77% vs 8,
17% p,0.001 ) compared with those directly admitted. There was
a borderline significant increase in stroke among transferees (11,
38% vs 8, 17%; p = 0.06) and CHF (7, 32% vs 4 9%; p = 0.10) and
no difference in the numbers of cases with symptoms longer than 1
month (5, 17% vs 13, 28% p = 0.41) or length of hospital stay
(median 23 IQR 15–42 vs median 27 IQR 14–42, p = 0.56).
Diagnosis
Blood cultures were drawn in all 77 patients with HE. Three of
four patients with negative blood cultures had received antibiotics
in the previous seven days. Additional culture positive sites were
heart valves (20), joint fluid (2), pacemaker wires (1), urine (1), and
other (5). One patient was diagnosed by PCR of infected tissue.
Echocardiography was performed in 97% of HE (transthoracic
only 15, transesophageal only 9, both transthoracic and trans-
esophageal 51). Vegetations were identified in a lower proportion
in HE than non-HE (71% vs 83%, p = 0.01) (Table 2). There was
no difference in the proportions of mitral and aortic valve
vegetations identified between HE and non-HE. Only 1 case of
tricuspid valve endocarditis was recorded in HE. New regurgita-
tion and paravalvular complications were not significantly
different from non-HE (Table 2).
Antimicrobial susceptibility testing
The causative organisms are shown in table 1. Of the isolates
tested 24/25 (96%) were penicillin susceptible (1 resistant strain of
A. aphrophilus), 48/49 (98%) were ampicillin susceptible (1 resistant
strain, of A. aphrophilus), 50/50 (100%) were ceftriaxone suscepti-
ble, and 30/32 (94%) were gentamicin susceptible (2 resistant
strains of H. parainfluenzae).
Treatment
Antimicrobial therapy was reported in 50 (65%) patients. Of
these 37 (74%) were treated with ceftriaxone (in combination with
an aminoglycoside in 17 and ampicillin in 6) , 6 with a penicillin
derivative (ampicillin in 3, penicillin G in 2, and penicillinase-
resistant penicillin in one,in combination with an aminoglycoside),
and 3 with cefazolin/cefalothin (in combination with an amino-
glycoside), and 4 unspecified. All cases of HE were treated with
antimicrobial agents that would be active as predicted by
Table 1. HACEK organisms isolated from definite and
probable cases of HACEK endocarditis.
HACEK organisms Number (%)
Haemophilus spp. 31 (40)
Haemophilus parainfluenzae 28 (36)
Haemophilus sp. othera 3 (4)
Aggregatibacter spp. 26 (34)
Aggregatibacter actinomycetemcomitans 15 (20)
Aggregatibacter aphrophilus 5 (6)
Aggregatibacter paraphrophilus 5 (6)
Aggregatibacter segnis 1 (1)
Cardiobacterium spp. 11 (14)
Cardiobacterium hominis 10 (13)
Cardiobacterium valvarum 1 (1)
Eikinella corrodens 4 (5)
Kingella spp. 4 (5)
Kingella kingii. 2 (3)
Kingella denitrificans 1 (1)
Kingella sp. 1 (1)
HACEK (not otherwise specified) 1 (1)
Total 77
anot specified.
doi:10.1371/journal.pone.0063181.t001
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susceptibility testing. Cardiac surgery was performed on 31 (40%)
patients a median of four days (IQR 1–19) after admission. The
aortic valve was replaced in 17 patients, mitral valve in 13,
tricuspid valve in one and an intracardiac device was removed in
one patient.
Outcomes
The in-hospital mortality of HE was less than one quarter that
of the non-HE (3, 4% vs 998,18%; p,0.001). Of the three HE
deaths with one had been treated surgically. Heart failure was
significantly less frequent in HE than non-HE (15% vs. 30%,
Table 2. Important features of HACEK endocarditis compared with all other causes of infective endocarditis in database*.
HACEK Endocarditis n=77
Non-HACEK Endocarditis
n =5514 P value
Clinical Features
Median age (interquartile range), y 47.4 (35.6–57.1) 60.5 (45.3–72.7) ,0.001
Prosthetic valve endocarditis 27/77 (35) 1298/5514 (24) 0.07
Manifestations .1 month 18/77(23) 1174/5294(22) 0.68
Osler’s nodes 5/71 (7) 132/5260 (3) 0.02
Conjunctival haemorrhages 6/72 (8) 214/5261 (4) 0.07
Vascular/immunologic evidence of endocarditis 25/77 (32) 1118/5514 (20) 0.008
Risk factors
Diabetes mellitus 6/77 (8) 962/5417 (18) 0.02
Health care-associated 1/77 (1) 1349/5514 (24) ,0.001
Congenital heart disease 11/66 (17) 533/4813 (11) 0.16
Native valve predisposition 25/76 (33) 1609/5403 (30) 0.55
Mechanical aortic valve 12/77 (16) 504/5507 (9) 0.07
Bioprosthetic aortic valve 6/77 (8) 426/5507 (8) 0.9
Mechanical mitral valve 11/77 (14) 404/5504 (7) 0.03
Other 5/77 (7){ 604/5504 (11) 0.27
Diagnosis
Blood culture growth 73/77 (95) 4586/5430 (84) 0.01
Other specimens culture positive 29/76 (38)` 2787/5489 (51) 0.03
ECHO findings
Intracardiac vegetations 53/75 (71) 4455/5383 (83) 0.01
Aortic Valve 26/53 (49) 1959/4455 (44) 0.49
Mitral Valve 25/53 (47) 2043/4455 (46) 0.9
Tricuspid Valve 1/52 (2) 578/4394 (13) 0.02
Other 4/53 (8)1 611/4455 (14) 0.23
New regurgitation 46/75 (61) 3124/5368 (58) 0.62
Paravalvular complications 15/75 (20) 1117/5354 (21) 0.85
Outcome
Stroke 19/76 (25) 898/5410 (17) 0.05
Embolic stroke 10/18 (56) 648/780 (83) 0.008
Haemorrhagic stroke/intracranial haemorrhage 8/18 (44) 132/780 (17) 0.006
Congestive heart failure 11/74 (15) 1646/5397 (30) 0.004
Embolization, excluding central nervous system 15/73 (21) 1205/5399 (22) 0.79
Intracardiac abscess 14/75 (19) 721/5402 (13) 0.17
Mycotic aneurysm 3/74(4) 104/5351 (19) 0.15
Surgery 31/77 (40) 2433/5482 (44) 0.49
Median days in hospital (interquartile range) 23 (15–42) 28 (15–44) 0.19
In-hospital death 3/77 (4) 998/5508 (18) 0.001
Death within 1 year of admission 6/57 (11)** 1627/4208 (39)** 0.001
*Values are reported as n/n (%), unless otherwise noted.
{Aortic valve- homograft 1, unknown repair 1; mitral valve – repair with prosthesis 1, other 2. TEE = Transesophageal ECHO.
`Specimens that were culture-positive were heart valve (20), joint fluid (2), pacemaker wire (1), urine (1) and other (5) 1Myocardial wall 2, chordae 1, intracardiac device
1.
**1 year mortality data was available on 57(74%) of HE and 4208(76%) of non-HE subjects.
doi:10.1371/journal.pone.0063181.t002
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p = 0.004). Stroke complicated a higher proportion of cases with
HE than non-HE (25% vs. 17%, p = 0.05) and there was a relative
excess of haemorrhagic stroke over embolic stroke in HE (44% vs
17%, p = 0.006). The presence of a stroke increased the length of
stay by 20 days despite occurring in a significantly younger age
group (Table 3). On multivariable regression analysis the
independent factors associated with stroke were increasing age in
10 year intervals (OR 0.62; CI 0.49–0.90; p,0.01) and mitral
valve vegetations (OR 3.60; CI 1.34–9.65; p,0.01). Eleven of 25
(44%) cases of HE with mitral valve vegetations suffered a stroke
compared with 484/2009 (24%) in non-HE (p = 0.03). The
frequency of systemic embolization, excluding central nervous
system, intracardiac abscess and mycotic aneurysm were not
significantly different in HE than non-HE (Table 2).
At one year follow-up, three additional cases of HE had died
(heart failure 1, unrelated causes 1, unknown 1); however the
cumulative death rate was significantly lower than non-HE (6,11%
vs 1627, 39%; p,0.001) (Table 2). Four cases had undergone
valvular surgery; three had been treated medically and one
surgically.
There was one possible relapse 4 months after completing
therapy with an unspecified HACEK organism. This organism
was not available for further speciation. In addition one patient
with HE had another episode of endocarditis with a methicillin
susceptible S. aureus.
HACEK native and prosthetic valve
endocarditis. Comparison of the clinical features of native
valve and prosthetic valve HE demonstrated that native valve HE
occurred at an older age (median 56.3 (range 41–67) vs median
43.8 (range 32–54) years, p = 0.003), and that a higher proportion
had Osler’s nodes (5, 20% vs 0, 0%; p = 0.002) and systemic
embolization (10, 37% vs 5, 12% v; p = 0.01) than prosthetic valve
HE (Table 4). There was no significant difference in the
proportion with stroke (7, 26% vs 11, 24%; p = 0.85), or congestive
heart failure (5, 19% vs 6, 14%; p = 0.74) or surgical treatment (8,
30% vs 22, 45%; p = 0.23) or length of median hospital stay
between these groups.
Of those with PVE 8 (30%) required surgical treatment and 19
(70%) were treated with medical therapy alone. There were no in-
hospital deaths in either treatment group. Of the 24 PVE patients
with 1 year follow-up data, there was one death (cause unknown)
and three who required cardiac surgery in the medically treated
group, but no deaths, relapses or further surgery requirement in
the surgically treated group. By comparison, among those with
native valve HE, there were two in-hospital deaths and 1 death
with-in the 1 year follow-up period.
Discussion
This report describes the findings of a large series of HE and
non-HE cases of bacterial endocarditis reported in a standardised
manner in which geographic distribution, frequency of clinical
features, risk factors and outcomes have been compared. Both
groups were subject to referral bias from transfers to the study
centres [19,20], but this is unlikely to confound these comparisons
as the proportion transferred was very similar in the two groups,
and the pattern of features of the transferees with HE was similar
to that reported in the ICE cohort. However the frequency of
some clinical features are influenced by transfers between
hospitals, and the results need to be interpreted in the light of
this limitation.
The marked geographic difference in the prevalence of HE (10-
fold) between the highest (New Zealand) and the lowest countries
(United States of America) confirms the findings of an earlier,
smaller sample of cases in the ICE cohort [11]. The range is
similar to the range of 0.8–6.1% reported in recent single and
multi-centre studies. [3–5]. The high prevalence of HE in New
Zealand is unlikely to be due to referral patterns given the low
proportion transferred from another facility. Other possible
reasons for the variation include the prevalence of risk factors
such as frequency of prosthetic devices [12], oral health [21],
Table 3. Univariate and multivariate analysis for the risk of stroke in HACEK endocarditis*.
No stroke Stroke
Univariate
analysis Multivariate analysis
n=57{ n=19{ P value
Odds Ratio (95% confidence
interval)
Prosthetic valve endocarditis 20/57 (35) 7/19 (37) 0.9
Median age (interquartile range), y 51 (38–60) 41 (25–54) 0.02 0.62; (CI 0.49–0.90) P,0.01
.1 month from 1st manifestation 13/57 (23) 5/19 (26) 0.8
Conjunctival haemorrhages 1/52 (2) 5/19 (26) 0.001
Osler’s nodes 4/52 (8) 1/18 (6) 0.8
Vascular/immunologic evidence of endocarditis 13/57 (23) 11/19 (58) 0.004
Aortic valve vegetation 22/37 (59) 4/16 (25) 0.02
Mitral valve vegetation 14/37 (38) 11/16 (69) 0.04 3.60 (CI 1.34–9.65) P,0.01
Aortic valve surgery 14/21 (67) 4/9 (44) 0.26
Mitral valve surgery 6/21 (29) 7/9 (78) 0.01
Embolization 10/56 (18) 5/17 (29) 0.3
Mycotic Aneurysm 0/57 (0) 3/19 (16) 0.003
Median days in hospital (interquartile range) 22 (14–34) 42 (21–60) 0.002
In-hospital death 2/57 (4) 1/19 (5) 0.7
*Values are reported as n/n (%), unless otherwise noted.
{There was missing data for stroke on one patient.
doi:10.1371/journal.pone.0063181.t003
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transmission pathways of HACEK organisms within populations
[22], regional health care access, and diagnostic bias.
Some clinical features varied with the causative species. H.
parainfluenzae was the commonest cause of HE, as has been
reported in population based studies [23]. H. parainfluenzae
endocarditis was less likely to have an insidious onset than both
A. actinomycetemcomitans and C. hominis confirming previous reports
[7]. C. hominis was strongly associated with aortic valve infection
and A. actinomycetemcomitans endocarditis was a frequent cause of
PVE, and vascular immunological manifestations [6,7,9,10].
Despite this, we found that HE has sufficient important clinical
features in common that distinguish it from non-HE to retain
clinical usefulness. These features include younger age of
presentation, community acquisition, a higher proportion with
vascular/immunological manifestations, a lower proportion with
co-morbidities and an excellent outcome.
Prosthetic valve endocarditis was common (35%), although the
prevalence of HACEK PVE was not significantly higher than non-
HE PVE in this study (p = 0.07). However, the comparator
includes a heterogeneous group of organisms with variable
propensity to cause PVE. For example, previous studies of the
ICE cohort have found the proportion of PVE in Staphylococcus
aureus IE to be 16%, viridans streptococcal IE to be 15%, and
coagulase-negative staphylococcal IE to be 32% [11]. Thus it
appears that HACEK organisms have a predilection for prosthetic
valves. This finding is more marked in late PVE (.1 year after
surgery) as HE causes late PVE in a large majority of cases [12],
but only about half of cases of S. aureus and coagulase-negative
staphylococci PVE, suggesting mechanical valves are a particular
risk for HE [17]. In addition this study may underestimate the true
proportion with PVE because of the high number of native valve
HE cases transferred from other centres. Pre-existing native valve
and congenital cardiac abnormalities were common in HE but
there was no significant increase in these conditions compared
with non-HE. Previous studies have suggested these risk factors
may occur more frequently in HE, but this will be subject to
changes in the epidemiology of native valve lesions such as
rheumatic fever and the widespread availability of cardiac surgery
[22].
Most cases of HE were treated with a third generation
cephalosporin and a minority with ampicillin with or without an
aminoglycoside; however there were insufficient cases to correlate
outcomes with these recommended regimens [24,25]. The
incidence of penicillin resistant strains was limited to an isolate
of A. aphrophilus species. b-lactamase producing strains of C. hominis
have been reported but not in A. actinomycetemcomitans to our
knowledge [26]. The proportion of all HE cases requiring cardiac
surgery (40%) was similar to non-HE and to that reported in the
literature [12,27]. However in PVE the requirement for surgery
was lower (30%) which compares favourably with published rates
for PVE overall (49%) [12,27]. The favourable outcome of both
medically and surgically treated HACEK PVE demonstrates that
HE is readily controlled and treated with antimicrobial agents
despite the presence of a prosthetic valve.
The outcome of HE was excellent overall with an in-hospital
mortality of 3% which is less than one quarter of the mortality for
non-HE and one sixth that of S. aureus endocarditis [28]. Heart
failure was diagnosed in 15% of cases compared with 30% in non-
HE, and 37% reported for S. aureus endocarditis [27,28]. The
younger age group and lack of co-morbidities, in addition to
pathogen-specific characteristics may favour a good in-hospital
and 1 year outcomes. These results would not be affected by
Table 4. Comparison between the features of native valve HACEK endocarditis and prosthetic valve HACEK endocarditis*.
Native valve Endocarditis
Prosthetic valve
endocarditis P value
n=47 n=27
Duke diagnosis definite 43/47 (92) 21/27 (78) 0.01
Median age (interquartile range), y 43.8 (32–54) 56.3 (41–67) 0.003
Osler’s nodes 0/43 (0) 5/25 (20) 0.002
Worsening of old murmur or presence of new murmur 30/47 (64) 8/27 (30) 0.005
ECHO evidence of new regurgitation 36/47 (77) 10/27 (37) ,0.001
Intracardiac vegetations 36/46 (78) 15/27 (56) 0.02
Aortic valve 17/36 (47) 9/15 (60) 0.4
Mitral valve 18/36 (50) 7/15 (47) 0.8
Aortic valve surgery 11/22 (50) 7/8 (88) 0.06
Stroke 11/46 (24) 7/27 (26) 0.85
Embolic 6/11 (55) 4/6 (67) 1.0
Intracerebral haemorrhage 5/11 (45) 2/6 (33) 1.0
Other systemic Embolization 5/43 (12) 10/27 (37) 0.01
Congestive heart failure 6/44 (14) 5/27 (19) 0.13
Surgery 21/47 (45) 8/27 (30) 0.23
In-hospital death 2/47 (4) 0/27 (0) 0.28
Median days in hospital (interquartile range) 21 (12–37) 24 (17–43) 0.2
Death within 1 year of admission 3/33 (9){ 1/22 (5){ 0.8
*Values are reported as n/n (%), unless otherwise noted.
{1 year mortality data was available on 33 (70%) subjects with native valve HE and 22(81%) subjects with prosthetic valve HE.
doi:10.1371/journal.pone.0063181.t004
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survivor bias given the very high survival rate of HE. With respect
to PVE, the numbers were too small to make meaningful
comparison for other major complications including stroke,
congestive heart failure and abscess formation.
The major complication of HE was stroke (25%), and this
complication almost doubled the length of hospitalisation. This
figure over-represents the true incidence of stroke in HE as there
was an increased frequency of stroke in those transferred from
other facilities. Nevertheless stroke is conspicuously common in
HE compared with non-HE, and the reported frequency in S.
aureus endocarditis (20%) and viridans streptococcal IE (8%) in the
ICE cohort [29]. Mitral valve IE was an important risk factor for
stroke as reported previously, but organism specific effects on the
nature of the vegetations in HE may also make a significant
contribution to the prevalence of stroke, as 44% of patients with
mitral valve HE suffering a stroke compared with 24% of non-HE.
This may be related to the long antecedent history with organisms
such as A. actinomycetemcomitans [7].
While embolism was the predominant cause of stroke in HE
there was relative excess of haemorrhagic stroke. The reasons for
this are not clear but it is possible micro-vascular/immunological
manifestations of IE which were significantly more frequent in HE
than non-HE and might contribute to the development of cerebral
microbleeds which are a strong predictor of subsequent intracra-
nial haemorrhage [30]. Anticoagulant therapy is unlikely to
contribute to the occurrence of stroke but may increase the
conversion of embolic to haemorrhagic events. [31].
There are several additional limitations of this study. Because of
small numbers both possible and definite cases were included to
increase statistical power. Despite this there were a limited number
of cases of HACEK endocarditis and the observational design and
long-term follow-up limited to one year limits our ability to draw
any firm conclusions regarding optimal antimicrobial therapy or
surgical treatment strategies. Furthermore the self selection of
centres to participate in the ICE study, and the heavy weighting
toward Europe, North America and Australasia with few sites in
Asia, and Africa has meant that the population sample may not be
representative of any specific region. Thus important geographical
differences may have been missed and any epidemiological
inferences from this study are limited.
Our findings suggest that there is sufficient similarity in
presentation and outcome to justify considering the HACEK
organisms as a group at present. Despite the high prevalence of
stroke, HE has a remarkably low mortality rate, suggesting that
current antibiotic therapy with surgery when needed, is very
effective. The reasons why HE shows apparent disparities in
geographical distribution, occurs in a younger age group, has a
propensity to infect prosthetic valves, and is associated with a high
incidence of stroke are worthy of further investigation.
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